Oragenics (NYSEAMERICAN:OGEN) Trading 2.6% Higher – Here’s What Happened

Oragenics, Inc. (NYSEAMERICAN:OGEN)’s stock price rose 2.6% during trading on Friday . The stock traded as high as $0.5899 and last traded at $0.5871. 39,441 shares changed hands during trading, a decline of 20% from the average session volume of 49,473 shares. The stock had previously closed at $0.5725.

Oragenics Price Performance

The stock’s 50 day moving average is $0.61 and its two-hundred day moving average is $0.72. The firm has a market capitalization of $2.65 million, a P/E ratio of -0.03 and a beta of 1.27.

Oragenics (NYSEAMERICAN:OGEN) last issued its earnings results on Friday, May 8th. The company reported ($0.51) EPS for the quarter.

Institutional Investors Weigh In On Oragenics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new position in Oragenics during the fourth quarter worth $26,000. Bank of America Corp DE lifted its position in Oragenics by 7,374.0% during the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after buying an additional 15,338 shares in the last quarter. DRW Securities LLC boosted its stake in shares of Oragenics by 82.4% during the 4th quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock worth $88,000 after buying an additional 50,900 shares during the last quarter. Finally, Sabby Management LLC acquired a new position in shares of Oragenics during the 3rd quarter worth about $77,000. 18.71% of the stock is currently owned by institutional investors and hedge funds.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.